IGC Pharma
5 hedge funds and large institutions have $29K invested in IGC Pharma in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.
625% more capital invested
Capital invested by funds: $4K → $29K (+$25K)
67% more funds holding
Funds holding: 3 → 5 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$23.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.74K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
1
Panagora Asset Management
Boston,
Massachusetts
| $23K | +$23.8K | +49,159 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $3K | +$2.74K | +5,654 | New |
|
3
Creative Planning
Overland Park,
Kansas
| $1K | – | – | – |
|
|
GI
4
Gradient Investments
Arden Hills,
Minnesota
| $1K | – | – | – |
|
|
LTFS
5
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
IGC Hedge Fund Activity: Q3 2016 in Review
5 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q3 2016, worth a combined $29K — up 625% from $4K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new IGC positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Panagora Asset Management, opening a new position worth an estimated $23.8K.
- 5 institutional investors held IGC Pharma (IGC) as of Q3 2016, up from 3 in Q2 2016.
- Funds reported $29K of IGC Pharma stock for Q3 2016, up 625% quarter-over-quarter.
- 2 funds opened new IGC Pharma positions in Q3 2016 and 0 closed out, a net change of +2 holders.
- The largest IGC Pharma buyer in Q3 2016 was Panagora Asset Management, an estimated $23.8K added.
Based on aggregated 13F filings for Q3 2016.